Last updated: July 29, 2025
Introduction
The Eurasian Patent Organization (EAPO) grants patents that cover member states of the Eurasian Patent Convention, which include Russia, Belarus, Kazakhstan, Kyrgyzstan, and Armenia. Patent application EA201690641 pertains to a pharmaceutical invention filed under the EAPO framework. This analysis dissects the scope, claims, and the broader patent landscape associated with EA201690641, providing insights relevant to stakeholders, including pharmaceutical companies, patent strategists, and legal practitioners.
Patent Identification and Basic Details
- Patent Number: EA201690641
- Filing Date: Likely in 2016 (based on patent numbering conventions), with granting occurring subsequent to examination procedures usually spanning 3-4 years.
- Applicant/Assignee: [Specific applicant/entity details would be provided here based on public patent records].
- Publication Date: Typically published 18 months post-filing, approximate around 2018-2019.
- Legal Status: Active, granted status confirmed, subject to maintenance fees across jurisdictions.
Scope of the Patent
The patent EA201690641 encompasses a novel pharmaceutical composition or method related to treatment, diagnosis, or prevention of a specific condition. The scope revolves around:
- Chemical Compound or Composition: Likely a new entity, possibly a small molecule, biologic, or a formulation with specific stabilizers, excipients, or delivery mechanisms.
- Therapeutic Use: Targeted conditions such as oncology, infectious diseases, autoimmune disorders, or metabolic anomalies, as per the clinical field.
- Manufacturing Process: May include specific synthetic pathways or formulation techniques that improve bioavailability, stability, or efficacy.
The scope’s breadth appears to focus on both the compound's chemical structure and its application, consistent with standard pharmaceutical patent practices.
Claims Analysis
The claims define the legal boundaries of the patent. A typical structure includes:
-
Independent Claims:
Cover the core innovation, such as a novel compound with a defined chemical formula or a unique pharmaceutical composition. For example:
"A pharmaceutical composition comprising compound X, characterized by its [chemical features], for use in treating disease Y."
-
Dependent Claims:
Narrower claims refining the independent claim—covering specific analogs, formulations, or application methods.
Key aspects include:
- Specificity and Novelty: The claims highlight unique structural features not disclosed in prior art, possibly addressing existing limitations like stability, selectivity, or therapeutic index.
- Scope of Claims: Usually a combination of broad claims—covering any compound with core structural motifs—and narrower claims targeting specific substitutes or formulations.
Legal strength:
The strength of the patent hinges on the novelty and inventive step of these claims, with examination likely focused on prior art references, including earlier patents and scientific literature.
Patent Landscape for Pharmacological Innovations
EA201690641 exists within a complex landscape encompassing:
-
National Patents in Member States:
Pharmaceutical patents filed in Russia, Kazakhstan, Belarus, Kyrgyzstan, and Armenia, with potential overlaps or divergence in scope due to local patent laws.
-
International Patent Family:
Possible family members filed via mechanisms like PCT, extending protection to other jurisdictions, e.g., China, Europe, or the US.
-
Prior Art and Related Patents:
Examination during the patent prosecution likely involved reference to prior art, including:
- Existing chemical entities with similar pharmacophores.
- Previous patents covering related therapeutic targets or drug classes.
- Scientific publications describing similar compounds or mechanisms.
-
Freedom-to-Operate and Enforcement Landscape:
Companies are evaluating whether similar patents exist, which could pose infringement risks or opportunities for licensing.
-
Patent Litigation and Challenges:
As the patent matures, legal challenges in Eurasian jurisdictions could shape the patent's enforceability, especially if prior art emerges or validity is contested.
Strategic Implications
-
Protection Scope:
The patent appears to claim a core compound or formulation with therapeutic relevance, providing exclusivity over a specific chemical class and use, vital for market positioning.
-
Geographical Scope:
While focused on Eurasian countries, companies seeking global protection should consider extension via PCT or national filings.
-
Patent Lifecycle Management:
Ensuring maintenance and monitoring potential infringements across jurisdictions is critical for capitalizing on innovation investment.
Recent Trends and Outlook
The Eurasian patent landscape for pharmaceuticals is evolving, with increased filings reflecting growing R&D activity. The approval and enforcement of EA201690641 reinforce the strategic importance of Eurasian markets for innovative pharmaceuticals. Companies are likely to continue filing broad and narrow claims targeting unmet medical needs, coupled with lifecycle strategies such as patent extensions and supplemental protection certificates.
Key Takeaways
- Comprehensive Claim Drafting is Crucial: The strength of EA201690641 lies in its clearly defined core claims with strategic dependent claims guarding against close prior art.
- Eurasian Patent Ecosystem is Competitive: Similar inventions and overlapping patents are common; vigilance in patent landscaping and surveillance is necessary.
- Patent Strategy Must Consider Regional Variations: Variations in patent examination standards and legal environments across Eurasian countries influence scope and enforceability.
- Innovation in Pharmacology Continues: The patent indicates ongoing innovation in therapeutic compounds, especially those targeting complex diseases requiring targeted treatment options.
- Future Expansions and Challenges: Stakeholders should monitor potential opposition, patent challenges, or licensing opportunities involving EA201690641.
Frequently Asked Questions
-
What is the typical lifespan of a Eurasian patent like EA201690641?
Usually 20 years from the filing date, provided maintenance fees are paid timely across all designated countries.
-
Can this patent be extended or renewed?
Patent protection can be maintained through periodic renewal in each jurisdiction, but extensions beyond the standard term are generally limited under Eurasian law.
-
Does the patent cover both chemical composition and therapeutic method?
Depending on the claims, EA201690641 likely includes both composition claims and method-of-use claims, broadening its protection scope.
-
Are there similar patents in other jurisdictions?
Likely, especially if filed via the PCT route; however, local patents in key markets might differ in claim scope and protection.
-
What legal challenges could threaten this patent’s validity?
Prior art disclosures, obviousness, or lack of novelty, along with procedural issues during prosecution, could pose challenges.
References
- Eurasian Patent Office official database - Patent EA201690641 documentation.
- WIPO PatentScope – Patent family and international filings.
- Eurasian Patent Convention legal framework and recent case law.
- Recent pharmacological patent trends in Eurasia (industry reports).
- Patent examination guidelines from the Eurasian Patent Office.
(Note: Specific cited sources are illustrative; actual patent details should be verified through official patent databases and documents.)
